516
Participants
Start Date
July 23, 2020
Primary Completion Date
December 7, 2021
Study Completion Date
January 25, 2022
Acetyllevocarnitine Hydrochloride Tablets
500 mg (2×250 mg/tablet) after meal, 3 times per day
Placebo
500 mg (2×250 mg/tablet) after meal, 3 times per day
Guangzhou First People's Hospital, Guangzhou
Huizhou Central People's Hospital, Huizhou
Affiliated Hospital of Zunyi Medical University, Zunyi
Hainan Third People's Hospital, Sanya
Handan Central Hospital, Handan
Hebei Petro China Center Hospital, Langfang
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Huaihe Hospital of Henan University, Kaifeng
Kaifeng Traditional Chinese Medicine Hospital, Kaifeng
Luoyang Third People's Hospital, Luoyang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Xinxiang First People's Hospital, Xinxiang
Henan Provincial People's Hospital, Zhengzhou
The Medical Group of Zhengzhou First People's Hospital, Zhengzhou
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
Taihe Hospital, Shiyan
Affiliated Hospital of Nantong University, Nantong
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Jiujiang Traditional Chinese Medicine Hospital, Jiujiang
The Fourth Affiliated Hospital of Nanchang University, Nanchang
Yichun People's Hospital, Yichun
Affiliated Hospital of Yanbian University, Yanbian
The First People's Hospital of Yinchuan, Yinchuan
Binzhou Medical University Hospital, Binzhou
Qingdao Central Hospital, Qingdao
Weihai Central Hospital, Weihai
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou
Beijing Hospital, Beijing
Beijing Luhe Hospital, Capital Medical University, Beijing
Beijing Pinggu Hospital, Beijing
Chongqing People's Hospital, Chongqing
Yongchuan Hospital of Chongqing Medical University, Chongqing
Tianjin First Central Hospital, Tianjin
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY